Xvivo Perfusion AB (publ) (LON:0RKL)
459.50
-3.84 (-0.83%)
At close: Feb 21, 2025
Xvivo Perfusion AB Revenue
In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M SEK with 37.63% growth. Xvivo Perfusion AB had revenue of 227.56M in the quarter ending December 31, 2024, with 46.12% growth.
Revenue
822.42M SEK
Revenue Growth
+37.63%
P/S Ratio
n/a
Revenue / Employee
4.84M SEK
Employees
170
Market Cap
1.07B GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |